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Purpose: Evaluate baseline factors that may explain the influence of study site on decisional conflict (DC) in men
from the Personal Patient Profile: Prostate (P3P) randomized trial.
Materials and methods: 476 cases from 5 P3P sites were included. Participants completed baseline demographic
assessments, 4 subscales of the DC scale at baseline (uncertainty, informed, values clarity, and support), the Expanded
Prostate Cancer Index Composite (short form) and the State-Trait Anxiety Inventory. Site data regarding typical
practices were collected. Linear regressions were used to model the relation between baseline DC scores and
study site adjusting for the list of variables.
Results: Baseline decisional uncertainly (p = 0.001) and informed (p = 0.03) subscales were significantly different
across sites. Participant demographic and baseline measures were significantly different (p < 0.05) between sites
except for trait anxiety. We identified participant level factors that explained study site differences at baseline for
the decisional uncertainty and values clarity subscales: a preferred treatment choice at study entry, whether the
study program was accessed at home vs. in clinic, number of doctors consulted pre-study, working status, state
anxiety, information from the media or a health care provider, and perceived knowledge level. State anxiety was
associated with higher DC across all subscales.
Conclusions: Individual characteristics of men seeking consultation for LPC were associated with DC at baseline,
not the site alone; anxiety contributed to higher conflict. These findings will inform future development and
implementation of the P3P and other decision support interventions.
Trial registration: NCT00692653.
Keywords: Localized prostate cancer, Decisional conflict, Decision-makingBackground
In 2014, prostate cancer will account for 27% of new
cancer cases and 10% of cancer related deaths in men
[1]. Over 90% will be diagnosed with localized prostate
cancer (LPC) [1]. There are a variety of care and treatment
“options” for men diagnosed with LPC including surgical
treatment, radiation treatment, or active surveillance.
There is little medical evidence to support the “best”* Correspondence: meghanl_underhill@dfci.harvard.edu
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unless otherwise stated.option for most men diagnosed with LPC and therefore
men often are asked to contribute to the care or treatment
decision. These decisions are complex and are made based
on a variety of personal and social economic factors, as
well as the side effect profile of each approach [2-6].
The Personal Patient Profile: Prostate (P3P) is a Web-
based intervention providing tailored, values-based
education and communication coaching to men making
decisions about management of LPC [7]. The P3P was
tested in a multi-site randomized control trial (RCT)
from 2007–2009 comparing standard patient education
plus P3P to standard patient education alone [8]. The 6al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(SPI) in Seattle, Washington; the University of Washington
(UW)/Seattle Cancer Care Alliance (SCCA) in Seattle,
Washington; Fox Chase Cancer Center (FCCC) radiation
oncology clinic in Philadelphia, Pennsylvania; and Veterans
Affairs Hospitals (VA) in Seattle, Washington; San Antonio,
Texas; and Augusta, Georgia.Table 1 Description of baseline participant characteristics and
Augusta Philadelphia San A
(n=91) (n=88) (n=25
Median (range) Median (range) Media
Age 62 (45–78) 66 (43–79) 62
N (%) N (%) N
College education or higher 23 25.3 51 58.0 6
Caucasian 39 42.9 84 95.5 12
Income 35K or less 54 59.3 7 8.0 8
Married/partnered 56 61.5 72 81.8 20
Working (yes) 40 44.0 55 62.5 11
Program access location
(at Clinic)
82 90.1 9 10.2 9
Having a treatment choice
at baseline
51 56.0 41 46.6 15
Number of doctors consulted
0 58 63.7 9 10.2 9
1 27 29.7 24 27.3 11
> 1 6 6.6 55 62.5 5
Perceived knowledge 34 37.4 67 76.1 7
Fair/A lot
Some 26 28.6 14 15.9 9
None/little 31 34.1 7 8.0 9
Information sources (yes)
Self 16 17.6 45 51.1 6
Health care provider 79 86.8 58 65.9 22
Media 49 53.8 77 87.5 16
Other people 58 63.7 72 81.8 15
STAI M SD M SD M
State anxiety 35.7 13.4 42.6 15.0 40.3
Trait anxiety 34.2 11.4 33.7 11.0 35.6
EPIC-SF questionnaire
Urinary irritative 87.5 16.5 93.8 11.1 87.5
Urinary incontinence 100 16.2 100 10.4 91.8
Bowel symptoms 100 13.4 100 9.7 95.8
Sexual symptoms 61.8 32.6 72.3 30.6 30.5
Hormonal symptoms 90 14.8 95 12.2 85
Note: M = Mean, SD = standard deviation STAI = State Trait Anxiety Inventory (scores r
Prostate Index Composite-Short Form (scores range from 0–100 with higher scores ind
comparing means and proportions across sites.The main outcome of the trial was decisional conflict over
6 months, measured by the validated Decisional Conflict
(DC) scale [9]. A total of 494 eligible cases participated
in the original study. A detailed description of the study
sample and procedures has been previously reported [8].
P3P was found to significantly reduce DC related to
making LPC treatment decisions over 6 months, adjustingstudy measures across study sites
Site p-value
ntonio Seattle UW-SCCA Seattle Puget Sound-VA
) (n=225) (n=47)
n (range) Median (range) Median (range)
(52–77) 62 (40–86) 63 (52–78) 0.03
(%) N (%) N (%)
24.0 168 74.7 18 38.3 <.0001
48 214 95.1 40 85.1 <.0001
32.0 16 7.1 24 51.1 <.0001
80.0 188 83.6 27 57.4 <.0001
44.0 137 60.9 19 40.4 .005
36.0 37 16.4 13 27.7 <.0001
60.0 96 42.7 33 70.2 0.003
<.0001
36 52 23.1 18 38.3
44.0 83 36.9 13 27.7
20.0 90 40.0 16 34.0
28.0 147 65.3 23 48.9 <.0001
36.0 57 25.3 8 17.0
36.0 21 9.3 16 34.0
24.0 102 45.3 16 34.0 <.0001
88.0 166 73.8 43 91.5 0.0005
64.0 192 85.3 23 48.9 <.0001
60.0 178 79.1 31 66.0 0.005
SD M SD M SD
16.3 40.6 12.2 39.0 11.9 0.009
12.9 32.5 8.8 36.0 11.2 0.16
18.2 87.5 15.8 87.5 14.8 0.02
16.8 100 12.8 100 13.9 0.02
13.2 100 9.8 100 12.0 0.04
29.4 78.5 26.9 66.7 28.5 <.0001
20.7 95 11.0 90 10.6 <.0001
ange from 20–80 with higher scores indicating more anxiety), EPIC-SF = Expanded
icating better HRQOL); One-way ANOVA and Chi-square test were used for
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sures [8].
In the primary multivariable analysis, even after control-
ling for participant personal characteristics and other study
measures, the study site at which participants received
consultation remained a significant predictor of DC [8,10].
The purpose of this analysis was to explore further the
factors that could potentially explain the influence of study
site on DC, focusing on site characteristics and pre-
intervention variables measured at baseline prior to entry
into the study and receiving consultation at the study site.
Methods
Participants
The study sites were described in detail elsewhere [8] and
summarized in Table 1. One participating site (SPI) en-
rolled only 18 participants, compared to 25 or more at all
other sites, and was therefore excluded due to small
sample size. 476 cases from 5 sites were included in this
analysis. Institutional Review Board approval was obtained
at each site for the original trial, with the University of
Washington/Fred Hutchinson Cancer Consortium as the
lead IRB site, and all participants had completed written
informed consent.
Measures
Participants in the original RCT self-reported personal
characteristics, concerns and preferences, all previously
documented [2] as important to prostate cancer treat-
ment decision making. Additional self-reported variables
included the number of doctors consulted about prostate
cancer treatment prior to study enrollment and level of
perceived knowledge about prostate cancer and its treat-
ment. Participants also were asked do you think you
know which treatment you want (yes/no) and how many
weeks has it been since your prostate biopsy. One item in
the original trial asked the participant to select what typeTable 2 Four subscales and items of the decisional conflict sc
Uncertainty • I am clear about t
Higher score = greater uncertainty • I feel sure about w
• This decision is ea
Informed • I know which opt
Higher score = less informed • I know the benefi
• I know the risks a
Values Clarity • I am clear about w
Higher score = lack of clarity about personal values • I am clear about w
• I am clear about w
Support • I have enough su
Higher score = lack of support • I am choosing wit
• I have enough ad
Responses for each item range from 0 (strongly agree) to 4 (strongly disagree); adaof prostate cancer information sources that had been
used prior to enrollment. This variable was re-coded
into four dichotomous (yes/no) variables related to
information source: self (books, pamphlets that I got
myself ), health care provider (books, pamphlets that my
health care providers gave me), media (magazines, news-
papers, Internet, television/videos), and other people
(family members, others).
The DC questionnaire [9] was completed at baseline.
Because the eligible participants all were scheduled for a
consult about a care or treatment decision and had not
made a final decision, only the first 4 DC subscales were
presented at baseline and included in this analysis: uncer-
tainty, informed, values clarity, and support (Table 2). Item
score responses ranged from 0 (agree) to 4 (strongly
disagree) with higher scores representing more conflict.
Subscale scores were transformed 0 (no DC) to 100
(extremely high DC) [11]. The Expanded Prostate Cancer
Index Composite (short form) (EPIC) was reported, meas-
uring prostate specific, health related quality of life
(HRQOL) [12]. Higher scores indicate better HRQOL in
the domains of irritative urinary symptoms, urinary incon-
tinence, hormone-related side effects, and bowel and
sexual function. Item scores were transformed to a 0 to
100 scale and the average scores within each subscale were
taken to create subscale scores [13]. The Spielberger
State-Trait Anxiety Inventory (STAI) was used to assess
baseline anxiety. Item scores for STAI are summated for
each subscale (state and trait) and scores range from
20–80 with higher scores indicating more anxiety [14].
Additional data about the study site clinical processes
were collected after the original trial and prior to the sec-
ondary analysis during interviews with study site
investigators. The investigators were asked to “Describe the
typical practices and process a man with localized prostate
cancer would follow from detection and biopsy to making a
care decision’. Investigators were prompted to reportale used at baseline [8,9]
he best choice for me.
hat to choose.
sy for me to make.
ions are available to me.
ts of each option.
nd side effects of each option.
hich benefits matter most to me.
hich risks and side effects matter most.
hich is more important to me (the benefits or the risks and side effects).
pport from others to make a choice.
hout pressure from others.
vice to make a choice.
pted from [7].
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regarding number of consultations, length of time between
biopsy and disclosure of results, and/or treatment decision
making, type of specialists at the site, length of time be-
tween consult visit, method of disclosing biopsy results,
and if educational material was given to patients. Based on
the responses, 5 categorical variables were created.
Statistical methods
Baseline patient characteristics and study measures were
compared among sites. One-way ANOVA and Chi-square
test were used for means and proportions, respectively.
All analyses were conducted using SAS (version 9.2).
For each of the four DC subscales, linear regression was
used to model the relation between baseline DC scores
and study site adjusting for personal characteristics (or
factors) and the site level variables. We explored whether
study site remained a significant variable associated with
baseline DC scores after adjusting for additional baseline
factors. First, univariate analysis was performed between
each factor. Factors that were potentially associated with
DC score, with significance levels (p-value) less than 0.2
were included in the multivariable model. Backward vari-
able selection was used to identify significant predictors,
where a variable was statistically significant if p-value ≤0.05
and kept in the model if p-value ≤0.2. Possible two-way in-
teractions among remaining predictors were examined.
Site level variables exhibited multi-collinearity with study
site and were not included in the multivariable model.
Results
Overview
The participant characteristics, including demographic, re-
ports of knowledge level, information source, anxiety andFigure 1 Mean scores together with 95% confidence interval (CI) desc
baseline across sites. *Note: Higher mean scores indicate more Decisiona
subscale p<0.001; Informed subscale p = 0.03; values clarity subscale p = 0symptom, were significantly different across sites (Table 1).
The men enrolled in Philadelphia at Fox Chase and at the
Seattle UW/SCCA were predominately college-educated,
Caucasian, working and had accessed the baseline P3P
measures on a personal computer or tablet. In contrast,
men enrolled in the Veterans Administration hospital sites
(Augusta, San Antonio and Seattle) were predominately
high school educated, not working, had accessed the base-
line measures in the clinic on a study computer and about
half were of minority race or ethnicity. Further, the major-
ity of men in Philadelphia and Seattle UW/SCCA had
already consulted with other physicians since the time of
biopsy, had retrieved prostate cancer information them-
selves and from media, and reported a higher level of
perceived prostate cancer knowledge.
Figure 1 illustrates the mean scores with 95% confi-
dence intervals (CI) for the four DC subscales measured
at baseline; baseline decisional uncertainly (p < 0.001)
and informed (p = 0.03) subscale scores were signifi-
cantly different across sites. The effect of the baseline
personal characteristics and reports of knowledge level,
information sources, anxiety and symptoms on DC sub-
scale scores were estimated in both univariate (Table 3)
and multivariable (Table 4) analyses.
Additional site level variables
Univariate analyses revealed sites that typically disclosed
the diagnosis in person in the clinic, provided more than
one in-person visit, took greater than one month between
biopsy to treatment decision, and did not conduct follow-
up by telephone had enrolled participants with signifi-
cantly less decisional conflict related to uncertainty. Sites
that provided educational information (handouts, books),
enrolled participants that reported significantly moreribing the variation in the four DCS subscales measured at
l Conflict; ANOVA testing mean difference across sites: Uncertainty
.12; support subscale p = 0.07.
Table 3 The influence of personal factors on decisional conflict subscale scores-results from the univariate analysis
Variable Decisional uncertainty Informed subscale Values clarity subscale Support subscale
Estimate p-value Estimate p-value Estimate p-value Estimate p-value
*Study center <.0001 0.03 0.13 0.07
Augusta −4.67 −2.72 −1.99 −7.00
Philadelphia 12.62 −1.10 2.60 −3.47
San Antonio −2.86 6.05 9.82 −7.02
Seattle UW-SCCA 13.66 5.37 2.61 −2.32
Age −0.24 0.17 0.87 0.62 0.81
Treatment preference at baseline (no vs. yes) 27.3 <.0001 16.6 <.0001 14.32 <.0001 8.40 <.0001
Education (college no vs. yes) −6.62 0.008 0.54 0.22 0.90
Income (>35K vs. <35k) 10.8 0.0002 3.64 0.16 0.63 0.60
Caucasian (no vs. yes) −14.5 <.0001 −4.39 0.12 0.52 −3.22 0.10
P3P access (Clinic vs. Not Clinic) −13.8 <.0001 −3.76 0.11 −5.72 0.007 −2.40 0.14
Married/partnered (no vs. yes) 0.93 0.28 0.58 4.51 0.01
Number of doctors consulted 0.0004 <.0001 0.003 0.002
0 vs. >1 13.55 7.94 5.64
1 vs. >1 5.54 2.10 −0.05
Working status (No vs. yes) −6.05 0.02 −3.08 0.16 0.27 0.86
Perceived knowledge 0.38 <.0001 <.0001 <.0001
Fair/A lot vs. some −19.52 −11.72 −3.87
None/little vs. some 3.76 6.88 7.73
**STAI
State anxiety 0.75 <.0001 0.50 <.0001 0.41 <.0001 0.44 <.0001
Trait anxiety 0.31 0.01 0.35 0.001 0.35 0.0002 0.43 <.0001
***EPIC scale
Urinary irritative symptoms −0.1 0.2 −0.1 0.18 0.17 0.61
Urinary incontinence symptoms 1.0 0.82 0.81 0.45
Bowel symptoms 0.1 0.39 0.62 0.65 0.92
Sexual symptoms 0.06 0.16 −0.08 0.02 −0.06 0.07 0.90
Hormonal symptoms −0.03 0.72 −0.2 0.02 −0.15 0.05 −0.16 0.005
Information Sources
Self (no vs. yes) −8.16 0.001 7.32 0.001 4.89 0.01 0.84
Health care provider (no vs. yes) 4.08 0.17 7.27 0.005 7.10 0.002 4.22 0.02
Media (no vs. yes) −13.98 <.0001 0.56 0.57 0.81
Other people (no vs. yes) 0.22 0.25 0.70 0.59
Note: Higher subscale scores indicate more decisional conflict; *Seattle/University of Washington VA is the reference group; **STAI = State Trait Anxiety Inventory;
***EPIC = Expanded Prostate Index Composite-Short Form.
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closed the diagnosis in person enrolled participants that
reported higher scores on the informed subscale and those
that had less than 1 month from biopsy to treatment
decision and gave educational handouts had participants
that reported lower DC on the informed subscale (data re-
ported in Table 5). These site level variables were collinear
with the overall study site variable and therefore not
included in subsequent multivariable analysis.Decisional uncertainty subscale
The baseline mean scores on the decisional uncertainly
subscale were significantly higher at the Philadelphia Fox
Chase radiation oncology site and the Seattle UW/SCCA
site (Figure 1). In univariate analysis (Table 3), not having
a treatment preference at baseline, Caucasian race, college
education, income greater than $35,000, accessing the P3P
intervention at home, working, having higher STAI scores,
and seeking information independently or from the media
Table 4 Factors that explain study site influence on decisional conflict-results from the multivariable analysis
Variable Decisional uncertainty Informed subscale Values clarity subscale Support subscale
Est. p-value Est. p-value Est. p-value Est. P-value
*Study center 0.47 0.003 0.52 0.002
Augusta −5.58 −6.69 0.01
Philadelphia 0.96 −0.19 0.95
San Antonio 0.73 −7.56 0.04
Seattle UW-SCCA 5.83 0.51 0.84
Treatment preference at baseline (no vs. yes) 24.5 <.0001 10.92 <.0001 10.44 <.0001 4.87 0.0005
Caucasian (No vs. Yes) −4.30 0.16 −4.23 0.13
Intervention Access (Clinic vs. Not Clinic) −6.33 0.02 −6.17 0.01
Married/Partnered (no vs. yes) 2.95 0.07
Number of doctors 0.006 0.002 0.14 0.05
0 vs. >1 −5.68 0.01 9.18 4.9 4.51 0.01
1 vs. >1 −7.52 0.001 5.29 2.0 1.17 0.47
Working status (no vs. yes) −2.85 0.15 −4.25 0.03
Perceived knowledge <.0001 <.0001 <.0001
Fair/A lot vs. some −16.55 −10.55 −7.00 <.0001
None/little vs. some 3.03 5.41 2.45 0.26
**STAI
State 0.53 <.0001 0.39 <.0001 0.27 <.0001 0.36 <.0001
Trait −0.15 0.19
***EPIC scale
Sexual symptoms −0.07 0.04
Information source
Self (no vs. yes) 2.53 0.21
Health care provider (no vs. yes) 3.09 0.17 3.94 0.07
Media (no vs. yes) −7.74 0.002
Note: Higher estimates indicate more decisional conflict; *Seattle/Puget Sound Veteran’s Administration Hospital is the reference group; **STAI = State Trait
Anxiety Inventory; ***EPIC = Expanded Prostate Index Composite-Short Form.
Table 5 Univariate analysis of the relationship between decisional conflict and the additional site level
variables collected
Site Variable Decisional uncertainty subscale Informed subscale Values clarity subscale Support subscale
Est. p-value Est. p-value Est. P-value Est. P-value
Number of in person visits (>1 vs. . 1) −14.5 0.008 2.97 0.55 7.55 0.09 −4.72 0.16
Diagnosis disclosure method .0001 0.09 0.96 0.85
In person vs. telephone −14.7 <.0001 −3.27 0.31 0.85 0.77 −0.12 0.96
N/A vs. telephone −1.0 0.75 −6.47 0.03 −0.11 1.0 −1.16 0.57
Time from Biopsy to treatment decision 0.0001 0.09 0.96 0.85
<1 mo vs. N/A 1.0 0.75 6.47 0.03 0.01 1.0 1.16 0.57
> 1 mo vs. N/A −13.6 0.001 3.21 0.40 0.86 0.10 1.04 0.69
Educational material given (no vs. yes) 7.16 0.008 5.03 0.04 −0.37 0.87 0.69 0.68
Telephone follow-up given (no vs. yes) −14.5 0.008 2.97 0.55 7.55 0.09 −4.72 0.16
Note: Higher estimates indicate more decisional conflict.
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certainty scores. Seeing more than one doctor also was
associated with higher decisional uncertainty scores.
When participant level variables were entered in the
multivariable model, site was no longer a statistically
significant (p = 0.47) predictor of DC (Table 4). Lower
decisional uncertainty was significantly associated with a
treatment choice at study entry and accessing the P3P
program in the clinic. Higher uncertainty was significantly
associated with having seen more than one doctor, higher
state anxiety, and obtaining information from the media.Informed subscale
Variables that were associated in univariate analysis
(Table 3) with lower scores on the informed subscale were
not having a treatment decision at study entry, high state
anxiety, accessing P3P at home, having less knowledge, and
no pre-study sexual or hormonal symptoms. Higher scores
on the informed subscale were significantly associated with
seeking information independently or from a health care
provider.
Though all potential baseline variables trending towards
significance in the univariate model were included in the
multivariable analysis (Table 4), study site remained a
significant factor (p = 0.003) for the informed subscale.
The aspect of DC related to being informed was signifi-
cantly lower at the Augusta site, meaning participants at
this site reported a perception of being more informed.
Participants who reported having a treatment preference
at study entry, seeing more than one pre-study doctor,
having sexual function issues, and higher prostate cancer
knowledge reported being more informed. Not working
and higher state anxiety scores were significantly associ-
ated with a report of being less informed.Values clarity subscale
Not having a decision at baseline, accessing P3P at
home, reporting less knowledge, higher STAI, and no
hormonal symptoms were significantly associated with
having higher values clarity scores, indicating more
conflict in univariate analyses (Table 3). Seeking infor-
mation independently or from the health care provider
was associated with lower scores indicating more values
clarity. Multivariable analyses (Table 4) indicated that
study site was not significantly (p = 0.52) associated
with values clarity. State anxiety was significantly asso-
ciated with a lack of values clarity (higher subscale
score). Lower values clarity subscale scores, indicating
less conflict, were associated with having a treatment
preference at study entry, accessing the study program
at the study site and reporting a higher level of prostate
cancer knowledge.Support subscale
In univariate analyses (Table 3), having seen more than
one doctor pre-study, having a treatment decision at study
entry, reporting more knowledge, and baseline hormonal
symptoms were associated with lower DC related to sup-
port needed to make a decision. Higher state and trait
anxiety, being single, fewer pre-study consults, were sig-
nificantly associated with conflict related to less support.
Study site remained a significant factor (p = 0.002)
after conducting the multivariable analysis (Table 4).
Participants enrolled at the Augusta and San Antonio
VA hospitals reported significantly less DC related to sup-
port at baseline. Factors associated with lower support
subscale scores, and therefore having enough support for
the decision thus far, were: having a treatment preference
at study entry, having seen more than one doctor pre-
study, and reporting a higher level of prostate cancer
knowledge. Higher state anxiety scores were significantly
associated with higher DC support scores.
Discussion
In the multisite P3P trial, the study site where partici-
pants received consultation served significantly differ-
ent patient populations and study site was a significant
factor associated with the main outcome of DC at
6 months. The current analysis explained what factors
played a role in the significance of study site for two of
the four DC subscales, uncertainty and values clarity.
For the remaining two subscales included in this ana-
lysis, informed and support, study site remained signifi-
cant. Potentially unmeasured variables play a role in
why study site is important for these subscales and fu-
ture trials will measure study site specific variables as
well as participant factors.
The primary finding from our secondary analysis docu-
ments that the characteristics of men who sought treatment
at the sites were explanatory of baseline DC measures. Dis-
proportionate numbers of men with certain characteristics
were consulted at the various study sites. The results high-
light how men from diverse backgrounds engage in the
complexity of decision making for LPC treatment. Race
was implicated in univarate analysis of uncertainty, but did
not predict DC once entered into the multivariable model.
For those men with higher socioeconomic status, such as
those at the Philadelphia Fox Chase radiation oncology site
and the Seattle UW/SCCA, with access to information and
health care resources, who sought information independ-
ently, and accessed Web-based information and multiple
doctors to discuss treatment options (by default at the radi-
ation site), DC related to uncertainty was higher. These
men may have known the complexity of the LPC treatment
decision at study entry, and therefore experienced more
conflict. In contrast, men with lower socioeconomic status,
such as those from the VA hospital sites, who did not
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formation independently may have been less aware of the
complexities and implications of the multiple treatment
options available for LPC, and therefore experienced less
conflict at study entry.
The significant influence of scores from the EPIC hor-
monal symptom domain was an interesting finding in the
univariate analysis for three of four DC scales, though not
sustained in the multivariable model. Men at the San
Antonio VA had significantly worse scores in this domain.
Certainly, at diagnosis these men had not been exposed to
any androgen suppressive therapies. Two of the items
within this domain inquire about depression and energy;
this may help explain the relationship between the EPIC
hormonal domain scores and DC.
Having a preferred treatment choice at study entry and
having higher perceived knowledge were important factors
that contributed to lower DC across subscales. It is im-
portant to recognize that having perceptions of a preferred
treatment decision and having high perceived knowledge
prior to having had LPC treatment related consultation
does not equate with actual knowledge about LPC treat-
ment options. A descriptive study [15] evaluating prostate
cancer related knowledge in 109 men with and without a
prostate cancer diagnosis from low income settings, found
low to moderate levels of prostate cancer knowledge and
comprehension in the sample. The findings that of the age
appropriate men, fewer than half knew the various pros-
tate cancer treatment options and less than a fourth knew
the potential side effects of treatment, may help place our
findings in context. Men with low socioeconomic status
may perceive themselves as having adequate knowledge
but still require more informational support related to
prostate cancer and treatment. In a recent publication,
Kaplan et al. [16] reported baseline factors that predicted
DC scores in men with LPC from a VA clinic. They re-
ported that lower prostate cancer knowledge was associ-
ated with higher DC and uncertainty at baseline. In the
P3P RCT, men at sites, such as the Seattle VA site, that
had the lowest baseline DC scores, indicating men were
the least conflicted, actually had the largest difference
between control and intervention groups with regard to
overall DC scores six months from enrollment [8]. Our
secondary analysis helps us understand that participants
who were not as prepared at baseline may have been less
aware of the complexity of the decision and, the educa-
tional and coaching component of the P3P intervention
benefited these men over time as they engaged in the
complex task of a shared decision.
If a man had high state, or situational, anxiety at study
entry, he was more likely to have higher DC across all
subscales. State anxiety is a modifiable factor that could
be addressed by clinical teams providing consultation for
LPC treatment. Davison and colleagues [17] reportedsignificantly lower state anxiety in men with newly diag-
nosed prostate cancer six weeks after randomization to an
informational intervention. In 2012, the American College
of Surgeons Commission on Cancer proposed a 2015
mandate for cancer care settings that the management of
distress, that includes anxiety, should be a component of
all patient care [18].
Limitations to our findings are important to identify.
Study site process variables were measured by investigator
recall and the current analysis may not have included all
necessary site information, potentially missing important
contributions that unknown study site variables may have
made to the results.Clinical implications
Clinicians who consult with men regarding management
of LPC may use these findings to better support men
and decrease DC. Anxiety could be assessed at baseline
to help clinicians understand which patients are likely to
feel most conflicted when making a treatment decision
and then target support to specific patient needs. Clinical
centers which serve a high proportion of men with no
access to the Internet and who are typically not consulting
with multiple clinicians may want to assure (not assume)
that men have a full understanding of prostate cancer and
options for treating or monitoring the condition.Conclusions
Individual characteristics of men seeking consultation
for localized prostate cancer were associated with DC at
baseline and men with these characteristics were en-
rolled disproportionately at the various sites. While the
original impact of the P3P intervention was positive des-
pite these site differences, we now understand more of
the influential baseline factors, notably information ac-
cess and perceptions of knowledge about prostate cancer
options. The modifiable factor of anxiety was identified
as contributing to higher conflict at baseline. These find-
ing will inform future development and implementation
of the P3P and other decision support interventions.
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